HIV-1 TAT Clade-D

HIV-1 TAT Clade-D Recombinant
Cat. No.
BT23342
Source
Escherichia Coli.
Synonyms
Appearance
Sterile Filtered and lyophilized, though might appear as a solution as a result of the glycerol content.
Purity
Greater than 90.0% as determined by SDS-PAGE.
Usage
Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock
Quick Inquiry

Description

HIV-1 TAT Clade-D Recombinant produced in E.coli is a single, non-glycosylated, polypeptide chain having the Accession number: AY194029.

Product Specs

Introduction
The HIV-1 Tat protein is essential for the replication and infectivity of the human immunodeficiency virus type-1 (HIV-1). This regulatory protein, active during the acute infection stage, is released by infected cells and absorbed by surrounding cells. This process promotes viral replication and increases infectivity. HIV-1 Tat achieves this by activating the transcription of HIV-1 viral genes, a process that involves inducing phosphorylation of RNA polymerase II's C-terminal domain (RNAPII). However, Tat can also negatively impact cellular metabolism by inhibiting the proliferation of antigen-specific T lymphocytes and triggering cellular apoptosis. This apoptosis is partly attributed to Tat's disruption of microtubule polymerization. LIS1, a microtubule-associated protein, plays a role in facilitating microtubule polymerization.
Description
Recombinant HIV-1 TAT Clade-D, produced in E.coli, is a single, non-glycosylated polypeptide chain. Its accession number is AY194029.
Physical Appearance
While typically a sterile filtered and lyophilized powder, the presence of glycerol may give it a solution-like appearance.
Formulation
Lyophilized form with 10% glycerol.
Purity
SDS-PAGE analysis indicates a purity greater than 90.0%.
Solubility
For reconstitution, dissolve the lyophilized HIV-1 TAT in sterile 18MΩ-cm H2O to a concentration of at least 100µg/ml. This solution can be further diluted with other aqueous solutions as needed.
Stability
Lyophilized HIV-1 TAT remains stable at room temperature for up to one week. For extended storage, desiccate and store below -18°C. Reconstituted HIV-1 TAT should be stored at 4°C for 2-7 days. For long-term storage, add a carrier protein (0.1% HSA or BSA) and store below -18°C. Avoid repeated freeze-thaw cycles.
Source
Escherichia Coli.

Product Science Overview

Introduction

Human Immunodeficiency Virus (HIV) is a complex virus with multiple subtypes and clades. Among these, the HIV-1 TAT Clade-D Recombinant is of particular interest due to its unique properties and implications in HIV research and treatment.

HIV-1 and Its Clades

HIV-1 is the most prevalent and pathogenic strain of the virus, responsible for the global HIV/AIDS pandemic. It is classified into several clades (A, B, C, D, etc.), each with distinct genetic and geographical characteristics. Clade D, primarily found in East and Central Africa, is known for its rapid disease progression and higher virulence compared to other clades .

The Role of TAT Protein

The Transactivator of Transcription (TAT) protein is a crucial component of HIV-1. It is one of the first proteins expressed after infection and is essential for the transcription of the HIV genome . TAT enhances the efficiency of viral replication and plays a significant role in the pathogenesis of HIV by modulating the host’s immune response and promoting viral persistence .

Recombinant TAT Proteins

Recombinant TAT proteins are engineered versions of the natural TAT protein, designed to study its functions and develop potential therapeutic interventions. The HIV-1 TAT Clade-D Recombinant is specifically derived from the Clade D strain of HIV-1. This recombinant protein retains the functional properties of the natural TAT protein but allows for controlled experimental manipulation .

Significance in Research

The HIV-1 TAT Clade-D Recombinant is valuable in several research areas:

  1. Vaccine Development: Understanding the immunogenic properties of TAT can aid in developing vaccines that elicit strong immune responses against HIV .
  2. Therapeutic Interventions: Studying the interactions between TAT and host cells can lead to novel therapeutic strategies to inhibit HIV replication and mitigate its pathogenic effects .
  3. Pathogenesis Studies: The recombinant TAT protein helps researchers investigate the molecular mechanisms underlying HIV-induced immune dysregulation and disease progression .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Category

Service

Related Products

HIV-1 TAT Clade-A
HIV-1 TAT Clade-A Recombinant
Cat. No.
BT23041
Source
Escherichia Coli.
HIV-1 TAT Clade-B
HIV-1 TAT Clade-B Recombinant
Cat. No.
BT23127
Source
Escherichia Coli.
HIV-1 TAT Clade-B, Biotin
HIV-1 TAT Clade-B Recombinant, Biotin Labeled
Cat. No.
BT23226
Source
Escherichia Coli.
HIV-1 TAT Cys22
HIV-1 TAT Cys22 Recombinant
Cat. No.
BT23421
Source
Escherichia Coli.
THE BIOTEK
THE BioTek is a global biotech company offering highly purified proteins for research in cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem cells.
  • Contact
  • Address: 1925 E Maple Ave, El Segundo, CA 90245 United States
  • Phone : +1 201-285-7826
  • Email : info@thebiotek.com
  • Hours : Mon.-Fri. 9:00 AM - 5:00 PM
© Copyright 2024 Thebiotek. All Rights Reserved.